{"title":"Application of Metabolomics in Carcinogenesis and Cancer Prevention by Dietary Phytochemicals.","authors":"Rebecca Mary Peter, Xiaoyang Su, Ah-Ng Kong","doi":"10.1007/s40495-025-00396-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>In this review article, specific emphasis is on evolution of metabolomics in cancer research, metabolomics workflow, general understanding of liquid chromatography - mass spectrometry (LC-MS) based platform for quantitation of metabolites, their biological interpretation and the application in carcinogenesis and cancer prevention by dietary phytochemicals.</p><p><strong>Recent findings: </strong>Metabolomics is increasingly becoming a preferred approach for next generation metabolic screening and has profound impact on medical practice. Metabolomics describes the end products of biochemical processes which are greatly influenced by genetic and environmental factors. Metabolic alterations can be linked to potential biochemical reactions/enzymes and their corresponding genes. Thus, these results can be further validated via multi-omics approach including genomics, transcriptomics and proteomics. However, challenges exist within and between omic-domain data integration considering complex biochemical regulation including organism versus tissue versus cellular level processes, epigenetics, transcriptional and post translational modifications. Metabolomics can reflect the steady state or dynamic state of metabolism because metabolites are highly dynamic in space and time.</p><p><strong>Summary: </strong>Metabolomic analysis of biological samples exhibit the possibility to determine mechanism of action of anti-cancer agents, biomarker discovery and impact of genetic alterations.</p>","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"11 1","pages":"12"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11889054/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pharmacology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40495-025-00396-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/6 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose of review: In this review article, specific emphasis is on evolution of metabolomics in cancer research, metabolomics workflow, general understanding of liquid chromatography - mass spectrometry (LC-MS) based platform for quantitation of metabolites, their biological interpretation and the application in carcinogenesis and cancer prevention by dietary phytochemicals.
Recent findings: Metabolomics is increasingly becoming a preferred approach for next generation metabolic screening and has profound impact on medical practice. Metabolomics describes the end products of biochemical processes which are greatly influenced by genetic and environmental factors. Metabolic alterations can be linked to potential biochemical reactions/enzymes and their corresponding genes. Thus, these results can be further validated via multi-omics approach including genomics, transcriptomics and proteomics. However, challenges exist within and between omic-domain data integration considering complex biochemical regulation including organism versus tissue versus cellular level processes, epigenetics, transcriptional and post translational modifications. Metabolomics can reflect the steady state or dynamic state of metabolism because metabolites are highly dynamic in space and time.
Summary: Metabolomic analysis of biological samples exhibit the possibility to determine mechanism of action of anti-cancer agents, biomarker discovery and impact of genetic alterations.
期刊介绍：
Current Pharmacology Reports will: publish cutting-edge reviews on subjects pertinent to all aspects of pharmacology, including drug discovery and development.provide incisive, insightful, and balanced contributions from international leading experts.interest a wide readership of basic scientists and translational investigators in academia and in industry. The Current Pharmacology Reports journal accomplishes its goal by appointing international authorities to serve as Section Editors in key subject areas, such as: epigenetics and epigenomics, chemoinformatics and rational drug design and target discovery, drug delivery and biomaterial, pharmacogenomics and molecular targets and biomarkers, chemical/drug/molecular toxicology, absorption, distribution, metabolism and elimination (ADME), pharmacokinetics (PK) and pharmacodynamics (PD), Modeling & Simulation (M&S) and pharmacometrics, and other related topics in pharmacology including neurology/central nervous system (CNS), cardiovascular, metabolic diseases, cancer, among others. Section Editors for Current Pharmacology Reports select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided. This journal publishes on a bi-monthly schedule.Please submit here: https://www.editorialmanager.com/phar/default.aspx
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
